Cargando…

In vivo PET imaging of neuroinflammation in familial frontotemporal dementia

INTRODUCTION: We report in vivo patterns of neuroinflammation and abnormal protein aggregation in seven cases of familial frontotemporal dementia (FTD) with mutations in MAPT, GRN and C9orf72 genes. METHODS: Using positron emission tomography (PET), we explored the association of the distribution of...

Descripción completa

Detalles Bibliográficos
Autores principales: Malpetti, Maura, Rittman, Timothy, Jones, Peter Simon, Cope, Thomas Edmund, Passamonti, Luca, Bevan-Jones, William Richard, Patterson, Karalyn, Fryer, Tim D, Hong, Young T, Aigbirhio, Franklin I, O'Brien, John Tiernan, Rowe, James Benedict
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892378/
https://www.ncbi.nlm.nih.gov/pubmed/33122395
http://dx.doi.org/10.1136/jnnp-2020-323698
Descripción
Sumario:INTRODUCTION: We report in vivo patterns of neuroinflammation and abnormal protein aggregation in seven cases of familial frontotemporal dementia (FTD) with mutations in MAPT, GRN and C9orf72 genes. METHODS: Using positron emission tomography (PET), we explored the association of the distribution of activated microglia, as measured by the radioligand [(11)C]PK11195, and the regional distribution of tau or TDP-43 pathology, indexed using the radioligand [(18)F]AV-1451. The familial FTD PET data were compared with healthy controls. RESULTS: Patients with familial FTD across all mutation groups showed increased [(11)C]PK11195 binding predominantly in frontotemporal regions, with additional regions showing abnormalities in individuals. Patients with MAPT mutations had a consistent distribution of [(18)F]AV-1451 binding across the brain, with heterogeneous distributions among carriers of GRN and C9orf72 mutations. DISCUSSION: This case series suggests that neuroinflammation is part of the pathophysiology of familial FTD, warranting further consideration of immunomodulatory therapies for disease modification and prevention.